Category Archives: News

National Cancer Institute Launches Mole vs Melanoma Info Site

Are You at Risk for Skin Cancer?
Are You at Risk for Skin Cancer?

It’s important to understand the difference between common moles that often occur on the skin and melanomas. To the untrained eye, the two can look very similar, and they can result in people either worrying unnecessarily about the condition of their skin or overlooking skin irregularities that require immediate medical attention.

At Issels®, we’ve worked with many people who have been diagnosed with melanoma, and immunotherapy has been shown to be a very promising alternative to traditional cancer treatments. Even so, identification remains a serious challenge, and the National Cancer Institute has come up with a tool to help.

The Moles to Melanoma Tool

The Moles to Melanoma tool from the National Cancer Institute provides individuals with pictures that help to understand the three types of moles that can appear on the human body. They are:

  • Common Moles
  • Dysplastic Nevi (or DN)
  • Melanoma

Common moles are those that are non-cancerous, and their characteristics are not a cause for concern. Dysplastic Nevi moles are those that aren’t cancerous, but that possess qualities that would cause doctors to keep an eye on them for any changes that could indicate melanoma. Finally, melanoma is characterized by moles that fit into the ABCDE category of identification.

Are You Concerned About Melanoma?

If your family has a history of melanoma, or if you have moles that cause you to be concerned, this tool can be very useful for you. However, it’s important to remember that no diagnostic tool should ever take the place of a professional diagnosis from an experienced physician.

At Issels, melanoma can be treated with non-toxic melanoma immunotherapy. Contact us to learn more.

July is Bladder Cancer Awareness Month – Do You Know the Bladder Cancer Risk Factors?

Men Are More Likely to Get Bladder Cancer Than Women... Are You at Risk?
Men Are More Likely to Get Bladder Cancer Than Women… Are You at Risk?

This July, you may see people sporting a yellow ribbon for Bladder Cancer Awareness Month. What do you know about the risks for this type of cancer that accounts for five percent of all new diagnoses in the United States each year?

Demographic Factors

  • Bladder cancer is the fourth most common type of cancer in men. According to projections by the American Cancer Society, in 2016 new diagnoses of bladder cancer in men will outnumber women three to one.
  • Approximately 90 percent of bladder cancer occurs in people over the age of 55.
  • Caucasians are twice as likely as African-Americans and Hispanics to develop bladder cancer. Occurrences are also lower in Asian-Americans and American Indians.

Lifestyle Factors

  • Smoking is the most serious risk factor, tripling your chances of developing bladder cancer. In addition, roughly half of all bladder cancer cases with both men and women are caused by smoking.
  • The diabetes medicine Actos, along with certain dietary supplements, has been linked to an increased risk of bladder cancer.

Medical Factors

  • Previous chemotherapy or radiation treatment can increase your risk of developing bladder cancer.
  • While direct cause-and-effect of bladder cancer has not yet been established, a link has been found with chronic urinary tract infections or bladder and kidney stones.

Issels® Offers Non-Toxic Immunotherapy for Bladder Cancer

Patients at Issels® have been successfully treated with immunotherapy for bladder cancer as well as other common forms such as lung cancer, breast cancer and melanoma. Contact us to learn more about our cancer vaccines and other personalized, integrative treatment programs.

July is Bladder Cancer Awareness Month, Will You Be Wearing the Yellow Ribbon?

New Immunotherapy Drug Can Help Fight Bladder Cancer
New Immunotherapy Drug Can Help Fight Bladder Cancer

If you or someone you love has received a diagnosis of bladder cancer or is in stage four and have exhausted treatment options, NBC news reports that there may be new hope for immunotherapy treatment for bladder cancer. This information is timely as July is Bladder Cancer Awareness Month.

Immunotherapy treatments

Immunotherapy for bladder cancer works by treating a person’s immune system so it has the ability to fight cancer.

According to the NBC news article, “more successful approaches, involve training immune cells to recognize a patient’s specific tumors, or finding and amplifying a patient’s own tumor-specific immune cells.” Immunotherapy now appears to be the best course of cancer treatment for many patients.

New drug, new hope

Hope now lies in a drug newly-approved by the FDA called atezolizumab (brand name Tecentriq) that boosts the immune system to slow the spread of tumors in patients in the advanced stages of bladder cancer. It’s the latest development in immunotherapy for bladder cancer treatments and it has shown promising results.

In a study of 119 patients who received the drug as treatment revealed that growth stopped in the tumors in 24% of those patients in the advanced stages of bladder cancer. The drug also shrank the tumors by 30%. According to the research team, 21 of the original patients from 2014 who received the immunotherapy for bladder cancer are still in remission today.

Learn more about our non-toxic immunotherapy for bladder cancer by contacting Issels® Integrative Immuno-Oncology.

Could this be an Accidental Miracle for the Treatment of Breast Cancer?

Breast Cancer Myths BustedAwareness Month
Promising Immunotherapy Treatment Protocol for Breast Cancer

Researchers in the United Kingdom recently made an exciting breakthrough in breast cancer immunotherapy treatment. Ironically, the discovery they made was neither sought after nor expected.

An accidental miracle?

A group of surgeons at the University of Manchester set out to test the use of a two-drug combo on tumors between the times of diagnosis and surgical excision. The drugs in question, traztusumab (Herceptin) and lapatinib (Tyverb) had previously been used individually in treatment.

While the intent was to study the effects of the drugs on tumor biology, the surgeons were stunned at the dramatic but unanticipated results. After only 11 days, 87 percent of the 257 participants experienced a significant reduction in cancer cells, while 11 percent showed no cancer cells at all.

Implications for future breast cancer treatments

Each of the women participating in the study had a form of breast cancer known as human epidermal growth factor receptor 2, also referred to as HER2 positive breast cancer. Herceptin works by blocking growth signals to HER2 receptors on the surface of the cancer cells, while Tyverb does the same from within the cells.

According to lead researcher Nigel Bundred, the results are a promising sign for tailoring individual treatments with breast cancer patients. The team is “cautiously optimistic” about indications that taking the drugs immediately after diagnosis may eliminate the need for chemotherapy.

At our Issels® center, we consider factors such as lifestyle and environment to create personalized breast cancer immunotherapy treatment. Visit our website to learn more about our cancer vaccines, cell therapies and other non-toxic immuno-oncology protocols.

Hard to Fight Pancreatic Cancer Responds to Immunotherapy

New Cancer Treatment For Pancreatic Cancer
Pancreatic Cancer Treatment News: Chemotherapy Plus Immunotherapy

Pancreatic cancer is one of the more difficult forms to diagnose, resulting in a low survival rate. A recent study found that immunotherapy for cancer holds great promise for more effective treatment.

Current treatments for pancreatic cancer

Surgery is the best option for pancreatic cancer. Unfortunately, the tumors are often discovered too late for surgery to be feasible. Doctors are left to use chemotherapy and other methods to control the cancer.

Medical breakthrough with immunotherapy

Researchers at University of Rochester Medical Center in New York set out to find a treatment that could make pancreatic cancer more receptive to surgery. The test involved use of PF-0416309, an immunotherapy drug that targets immune cells in pancreatic tumors.

Subjects included 47 patients whose pancreatic cancer had begun to spread. Eight received chemotherapy alone, while the others received a combination of chemotherapy and the immunotherapy drug.

Most of those who received the combination experienced a halt in the tumor’s growth, which was double the rate projected by the research team. Some saw their tumors shrink, while in one patient the cancer disappeared.

What’s next?

Side effects forced three patients to drop out, but otherwise no one had side effects more serious than those with chemotherapy alone. The researchers now plan to extend the scope of the test with phase 2 trials.

Issels® is the leader in immunotherapy for cancer

For years, our Issels® center has been ahead of the curve on immunotherapy for cancer. Our treatment programs are created individually,

based on each patient’s specific needs. Visit our website to learn more about cancer vaccines and other non-toxic immunotherapy treatments.

Watch that Powder, Talc use May Cause Uterine Cancer

Talcum Powder Linked to Uterine Cancer
Talcum Powder Linked to Uterine Cancer

Experts have warned about the use of talcum powder for years, but these claims have been a source of controversy. Researchers have recently put that controversy to rest by publishing the results of a study linking talcum powder to uterine cancer.

Researchers at Brigham and Women’s Hospital found that using talcum powder in the genital area can lead to a higher risk of ovarian cancer in women. In fact, this cancer risk was shown to be about one-third higher in those who use talcum powder. Scientists who participated in this study are calling for manufacturers to place labels on talcum powder products so women who use them are informed of these risks. Talcum powder is believed to raise the risk of ovarian cancer if it gets into the vagina and reaches the upper genital tract.

This study was published shortly after a jury ordered manufacturer Johnson & Johnson to pay the family of a woman who died of uterine cancer $72 million. The family claims that the woman’s use of Johnson & Johnson’s talcum powder products led to her developing this deadly form of cancer.

The Brigham and Women’s Hospital study provides further evidence that there is a link between the use of talcum powder and an increased risk of ovarian cancer. While scientists state that more research is needed, many caution against using this type of powder, especially in the genital area.

Those who are interested in learning more about non-toxic treatments for uterine cancer should contact Issels®. We offer immunotherapy and other types of safe non-toxic treatments for many types of cancer.